New radioactive drug for advanced neuroendocrine tumors
Part of Cancer clinical trials.
This trial tests a new radioactive drug, Terbium-161 DOTATATE, for people with advanced neuroendocrine tumors that have stopped responding to a similar treatment called Lu-177 DOTATATE. It aims to see if this new drug is safe and can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a type of neuroendocrine tumor (called GEP-NET) that is well-differentiated and has spread or cannot be removed by surgery
- Your tumor shows strong activity on a special PET scan (Ga-68-DOTANOC) showing it can bind to the drug
- Your tumor has grown or worsened despite previous treatment with Lu-177 DOTATATE
- You are generally well enough to carry out daily activities (Karnofsky score at least 60 or ECOG score 0–2)
- Your kidney, liver, and blood cell levels are within safe ranges as checked by blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
This trial tests a new radioactive treatment, terbium-161, for men with advanced prostate cancer that has stopped responding to other treatments. It aims to see if this treatment can target and kill cancer cells.
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Hear when a new Neuroendocrine Neoplasms (Tumours) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.